Tenaya Therapeutics Appoints New Director, Adjusts Executive Pay
Ticker: TNYA · Form: 8-K · Filed: Jun 27, 2024
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: TNYA
TL;DR
Tenaya adds a director, Fenwick, and revises CMO Ali's pay package. Board changes incoming.
AI Summary
Tenaya Therapeutics, Inc. announced on June 25, 2024, changes to its board of directors and executive compensation. Specifically, the company elected Dr. Jeffrey J. Fenwick as a Class II director and appointed him to the Nominating and Corporate Governance Committee. Additionally, the company entered into a new employment offer letter with its Chief Medical Officer, Dr. Faraz Ali, effective June 25, 2024, detailing his compensation and benefits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and typically do not indicate significant operational risks.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- Dr. Jeffrey J. Fenwick (person) — Elected Class II Director
- Dr. Faraz Ali (person) — Chief Medical Officer
- June 25, 2024 (date) — Effective date of changes
FAQ
Who was elected as a new director for Tenaya Therapeutics?
Dr. Jeffrey J. Fenwick was elected as a Class II director.
What committee was Dr. Fenwick appointed to?
Dr. Fenwick was appointed to the Nominating and Corporate Governance Committee.
Who is the Chief Medical Officer of Tenaya Therapeutics?
The Chief Medical Officer is Dr. Faraz Ali.
What is the effective date of the reported changes?
The earliest event reported is dated June 25, 2024.
What type of company is Tenaya Therapeutics?
Tenaya Therapeutics, Inc. is a company in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) industry.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-06-27 17:10:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
Filing Documents
- tnya-20240625.htm (8-K) — 41KB
- 0000950170-24-078585.txt ( ) — 155KB
- tnya-20240625.xsd (EX-101.SCH) — 25KB
- tnya-20240625_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Leone D. Patterson, M.B.A. Leone D. Patterson, M.B.A. Chief Financial and Business Officer Date: June 27, 2024